Biogen Inc. Stock

Equities

BIIB

US09062X1037

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-06-07 pm EDT 5-day change 1st Jan Change
225.4 USD -2.83% Intraday chart for Biogen Inc. +0.22% -12.88%
Sales 2024 * 9.52B Sales 2025 * 9.56B Capitalization 33.78B
Net income 2024 * 1.94B Net income 2025 * 2.26B EV / Sales 2024 * 3.86 x
Net Debt 2024 * 2.99B Net Debt 2025 * 614M EV / Sales 2025 * 3.6 x
P/E ratio 2024 *
17.9 x
P/E ratio 2025 *
15.4 x
Employees 7,570
Yield 2024 *
-
Yield 2025 *
-
Free-Float 85.81%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.83%
1 week+0.22%
Current month+0.22%
1 month+2.97%
3 months+2.77%
6 months-5.73%
Current year-12.88%
More quotes
1 week
224.58
Extreme 224.58
237.54
1 month
210.33
Extreme 210.33
237.54
Current year
189.44
Extreme 189.44
268.30
1 year
189.44
Extreme 189.44
319.76
3 years
187.16
Extreme 187.16
427.50
5 years
187.16
Extreme 187.16
468.55
10 years
187.16
Extreme 187.16
480.18
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 22-11-13
Director of Finance/CFO 60 20-08-14
Chief Operating Officer - 14-12-31
Members of the board TitleAgeSince
Director/Board Member 75 09-12-31
Director/Board Member 70 19-06-18
Chairman 64 10-01-02
More insiders
Date Price Change Volume
24-06-07 225.4 -2.83% 916,910
24-06-06 232 -2.00% 887,370
24-06-05 236.7 +1.11% 947,930
24-06-04 234.1 +1.88% 1,016,693
24-06-03 229.8 +2.16% 1,220,813

Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT

More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows: - sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.; - royalties (17,2%) ; - other (9,1%): primarily revenues from partnership agreements.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
232 USD
Average target price
284.6 USD
Spread / Average Target
+22.70%
Consensus